The anticoagulant drug Xarelto (rivaroxaban) has recently been linked to blood clots, internal bleeding and other serious side effects. While the drug has been shown to require less intensive patient monitoring than its major competitor warfarin, reports have shown that in some patients, Xarelto may cause life-threatening blood clots and potentially irreversible internal bleeding episodes.
Free Xarelto Lawsuit Evaluation: If you or a loved one has been injured by Xarelto, you should contact our law firm immediately. You may be entitled to compensation by filing a suit against the manufacturer of Xarelto and we can help.
What is Xarelto?
Manufactured and marketed in a joint partnership between Jansen Pharmaceuticals (a Johnson & Johnson company) and Bayer HealthCare AG, Xarelto is an anticoagulant blood thinner designed to prevent the formation of blood clots. Xarelto was approved by the U.S. Food & Drug Administration (FDA) in July 2011 for the prevention of a type of blood clot known as deep vein thrombosis (DVT), a condition that commonly occurs after certain types of surgeries. The drug is also commonly prescribed to reduce the risk of stroke in patients with a certain type of heart rhythm disorder. Xarelto belongs to a class of drugs known as factor Xa inhibitors, which includes the much-troubled Pradaxa (generic: dabigatran).
‘ROCKET’ Safety Study
The largest clinical trial conducted to date on Xarelto was ROCKET (Rivaroxaban Once daily oral direct Factor Xa inhibition Compared with vitamin K antagonism for prevention of stroke and Embolism Trial). This study looked at data on over 14,000 patients and compared Xarelto to warfarin. ROCKET determined that Xarelto was no more effective than warfarin, and that the health risks associated with the drugs were similar. The most commonly reported side effect was internal bleeding, with rates similar to that of warfarin. However, Xarelto caused fewer brain bleeds and more bleeding events in the stomach and intestines.
Many experts have questioned the safety of Xarelto as a result of internal bleeding reports and the lack of antidote when these events occur. The FDA staff gave a negative review of Xarelto for patients with atrial fibrillation (afib), citing multiple problems with the ROCKET study. The agency requested that Janssen conduct additional research to better understand the link between Xarelto, internal bleeding and stroke.
In January 2012, Reuters reported that the U.K.’s National Institute for Health and Clinical Excellence (NICE) had refused to recommend or approve Xarelto for use in state health services until Bayer can provide more safety data on the drug. Other medications battling with Xarelto for dominance in the highly lucrative anticoagulant market include:
- Eliquis (generic: apixaban), made by Pfizer and Bristol-Myers Squibb. In September 2011, data was released which found that Eliquis causes fewer deaths and less bleeding than warfarin.
- Pradaxa (generic: dabigatran), manufactured by Boehringer Ingelheim.
- Lixiana (edoxaban), manufactured by Daiichi Sankyo.
Xarelto & Stroke
Blood clots in the brain can cause a transient ischemia attack (TIA), also known as a “mini-stroke”, which may precede a stroke. If blood flow is obstructed for more than a few seconds, the brain begins being deprived of blood and oxygen. Brain cells can die, causing permanent damage to the organ. Xarelto labels contain a boxed warning indicating that there is an increased risk of stroke after discontinuing use of the drug for the treatment of non-valvular afib. Increased stroke rates were observed during the transition from Xarelto to warfarin in clinical trials in afib patients.
Signs and symptoms of a Xarelto stroke may include:
- One side of the face may droop or become numb
- Sudden numbness or weakness in an arm or a leg
- Slurred speech or speech that is difficult to understand
- Sudden trouble seeing in one or both eyes
- Sudden trouble walking
- Sudden dizziness, loss of balance or coordination
- Sudden severe headache with no known cause
Xarelto has been linked to an increased risk for internal bleeding events. Signs and symptoms of Xarelto-induced internal bleeding may vary, depending on the location of the bleeding, and what body functions are affected. Symptoms of internal bleeding may include:
- unusual bleeding
- discolored urine (blood in the urine)
- red or black-colored stool
- coughing up blood
- vomiting blood that looks like coffee grounds
- frequent nose bleed or gum bleeding
- weakness and swelling in the extremities
According to a new study conducted by researchers in Australia, Xarelto presents less of a risk of bleeding in the brain than Coumadin (warfarin) when given to patients with atrial fibrillation, but like Pradaxa, Xarelto may cause more serious bleeding events that could be difficult to treat. The FDA has announced that it is currently in the process of evaluating bleeding events in patients being treated with Xarelto to determine whether the risks outweigh the benefits of the drug.
Although excessive bleeding events are the most commonly reported serious side effect associated with Xarelto, there has been increasing concern about the development of blood clots in patients who are administered Xarelto as a prophylaxis. These patients tended to be a younger group [median age 66] who took Xarelto after hip or knee replacement surgery. According to a report issued by the Institute for Safe Medication Practices (ISMP), of the 356 adverse events reported in the first quarter of 2012, at least 158 cases of blood clots or thromboembolic events were reported to the FDA.
Signs and symptoms of a Xarelto blood clot may include:
- exhaustion or unexplained fatigue
- redness, inflammation or varicose veins
- shortness of breath
- chest pain or pain with deep breathing
- fever or sweats
- dizziness or fainting
- increased heart rate
- unexplained cough
- asymptomatic (no symptoms)
- bloody mucus with worsening cough
JAMA Study Investigates Blood Clot Treatment Strategies
A September 2014 study published in the Journal of the American medical Association (JAMA) found that most treatment options for blood clots in veins (venous thromboembolism) were equally safe and effective, yet major bleeding events occurred more often in patients treated with anticoagulants like Xarelto. Researchers conducted 45 randomized trials on 44,989 test subjects, and found that 0.49% of Xarelto users suffered a major bleeding event during the first three months of treatment, compared to just 0.29% with Eliquis. The study’s authors concluded that, except for a UFH-vitamin K antagonist combination, all other treatment strategies had similar bleeding risks.
Xarelto Side Effects
In addition to having the potential to cause blood clots and serious internal bleeding events, Xarelto has also been associated with a number of other side effects including:
- brain hemorrhage
- epidural hematoma
- gastrointestinal bleeding
- pulmonary embolism
- severe allergic reactions (rash; hives; itching; difficulty breathing; tightness in the chest; swelling of the mouth, face, lips, or tongue)
- bloody or black, tarry stools
- coughing up blood
- dark urine
- sore throat
- pain or new drainage at wound sites
- pink or red urine
- red, swollen, blistered, or peeling skin
- stiff, sore, hot, or painful joint
- symptoms of anemia (e.g., unusual paleness, severe or persistent headache, shortness of breath, fast heartbeat, chest pain, unusual tiredness or weakness)
- symptoms of bleeding in the brain (e.g., sudden, severe headache; one-sided weakness; vision problems; slurred speech; confusion)
- symptoms of low blood pressure (e.g., fainting, light-headedness, severe or persistent dizziness)
- unexplained swelling
- unusual or prolonged bruising or bleeding
- vomit that looks like coffee grounds
- yellowing of the skin or eyes (jaundice)
Xarelto Bleeding Risk Increased in Acutely Ill, ACS Patients: Study
In November 2013, a study published in Medscape identified a link between Xarelto and a nearly 3-fold increased risk of bleeding in acutely ill patients, as well as a 4-fold increased risk of major bleeding in patients diagnosed with Acute Coronary Syndrome (ACS). These findings were based on data from four dozen clinical trials involving Xarelto, Pradaxa, Eliquis, Lixiana and darexaban, all of which have been approved since 2010. The study’s authors wanted to know how these drugs performed against each other, as well as how they compared to warfarin and heparin, staple anticoagulants that have been in use for more than 50 years in the U.S.
Bleeding events associated with the new drugs included:
- Hip surgery – 1.43-fold increased rate of major bleeding
- ACS – 3.27-fold increased rate of major bleeding
- Medically ill thromboprophylaxis – 2.79-fold increased rate of major bleeding
Are Xarelto Lawsuits Being Filed?
- February 2014: a lawsuit was filed on behalf of Virginia G. Stuntebeck, a Kentucky woman who allegedly experienced severe internal bleeding after taking Xarelto. That case is: Stuntebeck v. Janssen Research & Development LLC et al, Case Number 140201754; Court: Philadelphia Court of Common Pleas.
- May 2014: a wrongful death lawsuit was filed against Janssen and Bayer which stated that Xarelto caused the death of Mattie Edgin, who allegedly died after taking the drug. Edgin’s niece Della Wise, who filed the complaint, said that Xarelto was “fervently marketed … with no regard to the accuracy and misrepresentations of their misleading marketing.”
Wise accuses the companies of falsely claiming that Xarelto users do not need to undergo routine testing for internal bleeding or blood clots. She also noted that Xarelto does not have a reversal agent, unlike warfarin, which can be counteracted with a single dose of Vitamin K when bleeding events occur. The lawsuit seeks punitive damages, including fraud, wrongful death, consumer law violations, negligence, failure to warn, product liability, unreasonable marketing of a dangerous drug, and breach of warranty.
- June 2014: The wife of a man who allegedly bled to death after taking Xarelto filed a lawsuit against Janssen for failing to warn that the drug can cause uncontrollable bleeding events. The complaint was filed in federal court in Florida by Nancy Packard, on behalf of her husband, William N. Packard, Jr., who started taking Xarelto in January 2012 for the treatment of afib.
After using the drug for approximately 6 months, Mr. Packard developed bleeding in his brain and was hospitalized. Doctors were unable to stop the bleeding, even after drilling a burr hole in his skull, and Packard died on June 28, 2012. According to the complaint:
“Defendants failed to adequately warn about the lack of an antidote to reverse uncontrolled bleeding caused by Xarelto. Defendants merely indicated that there was a risk for bleeding and side-stepped the important issue of reversing the effects of Xarelto should a bleed occur. Other safer alternatives to Xarelto® have an antidote that can reverse uncontrolled bleeding.”
That case is: Nancy Packard v. Janssen Research & Development LLC et al; Case Number 9:14cv80831; U.S. District Court for the Southern District of Florida.
- October 9, 2014: An 87-year-old man who allegedly experienced severe internal bleeding after taking Xarelto filed a lawsuit against Janssen and Bayer. The plaintiff began using the drug on his doctor’s advice in early 2012, and suffered a gastrointestinal bleed on October 15, 2012. The lawsuit claims his injury was a direct result of Xarelto side effects, and seeks compensation for personal injuries, pain and suffering, and emotional distress.
Xarelto Lawsuits Formed into Multidistrict Litigation
The U.S. Judicial Panel on Multidistrict Litigation (JPML) has agreed to centralize all federally-filed Xarelto Lawsuits into a single proceeding to be established in the U.S. District Court, Eastern District of Louisiana. At least 21 lawsuits have been filed in federal court alleging that Xarelto caused plaintiffs to suffer life-threatening internal bleeding events and other serious complications, according to a transfer order issued Dec. 12. Click here to learn more.
European Xarelto Labels Updated to Include Guidance for A-Fib Cardioversion
Jan. 20, 2015 – Bayer today announced changes to Xarelto product information in Europe, according to the European Medicines Agency (EMA). The label update provides doctors with information regarding the clinical utility of Xarelto in patients with non-valvular atrial fibrillation who require cardioversion, and is based on the CHMP opinion issued Dec. 2014.
Can I File a Xarelto Lawsuit?
Only a qualified attorney can determine whether you are eligible to file a lawsuit against Janssen Pharmaceuticals, the maker of Xarelto, which is why we are currently offering free case evaluations. Simply fill out the confidential evaluation form below to contact our law firm now.
Most cases involving pharmaceuticals allege that a drug was sold with design, manufacturing, and/or marketing defects, which typically refers to a company’s failure to warn of a certain side effect. In the case of Xarelto, our attorneys suspect that patients may be able to take legal action in light of claims that Janssen failed to adequately warn doctors and patients about the risk of uncontrollable internal bleeding events.
How Can Filing a Lawsuit Help Me?
By filing a lawsuit against the maker of Xarelto, you may be entitled to collect compensation for:
- Financial hardship resulting from emergency visits, ongoing care and lost wages
- Emotional distress from caring for loved ones with serious medical problems
- Funeral expenses because of a death caused by Xarelto
- Holding Bayer and Janssen accountable for releasing a dangerous drug
Do I Have a Xarelto Lawsuit?
The Product Liability & Defective Drug Litigation Group at our law firm is an experienced team of trial lawyers that focus on the representation of plaintiffs in Xarelto lawsuits. We are handling individual litigation nationwide and currently accepting new internal bleeding cases in all 50 states.
Free Xarelto Lawsuit Evaluation: If you or a loved one was injured by Xarelto, you should contact our law firm immediately. You may be entitled to compensation by filing a Xarelto Suit and we can help.